To the Independent Members of the BOD:
Having set the wheels in motion to finally getting the attention of the SEC, let me address specifics of the 10-Q filing:
Page 8: "The first license agreement we executed with TheraCour on September 1, 2005". THIS FACT IS A BALD-FACED LIE.
Page 11: Under "Accounts Payable- Related Party" is the language found in the ACTUAL first license agreement of May 12, 2005, in which the word "HERPES" was granted by TheraCour as one of the 6 virus types licensed. As you know, when used a a stand-alone word, the definition includes VZV Shingles.
NNVC OWNS THE LICENSE TO SHINGLES, AND HAS SINCE THE INCEPTION OF THE COMPANY.
Page 11: Anil talks about mortgaging the lab. DON'T AGREE TO THIS. HE HAS FOR THE LAST 2 YEARS PURSUED HIS PLAN TO BANKRUPT THE COMPANY AND REFUSED TO RAISE CAPITAL THROUGH THE SALE OF COMMON STOCK. TAKING ON DEBT, TOGETHER WITH FURTHER ORCHESTRATED DELAY, WILL ONLY HASTEN THE BANKRUPTCY FILING.
What you must do if we have any hope of saving this company:
1, Terminate Anil for committing the fraud in the Amended License Agreement, which he now calls the "FIRST".
2. Fire Meeta for knowing of her husband's fraud while being an officer of the Company bound by its Code of Conduct.
3. Stan and Mukand should thereafter resign, as being incompetent these many years as Directors.
4. As the last remaining Board member, Jim should immediately appoint Gene and Vivien to fill the two vacant seats, as Independent Directors.
5. Milton should loan the Company, interest free, $10 Million as a convertible note, with a 3 year maturity, convertible at 50 cents per share, "being finally the best he can be".
6. The newly configured BOD should then rehire Irach to manage the Company, with Jim becoming CEO. Together they should hire Meeta's replacement.
Sincerely,
Dianne B
Dave Morse
The Whistleblower Team at NanoViricides, Inc. (NNVC)
Filed with the SEC on November 17, 2018
On Thu, Feb 14, 2019 at 10:06 PM
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934.
For the quarterly period ended December 31, 2018
Commission File Number: 001-36081
NANOVIRICIDES, INC.
(Exact name of Company as specified in its charter)
| NEVADA |
| 76-0674577 | | (State or other jurisdiction) |
| (IRS Employer Identification No.) | | of incorporation or organization) |
|
|
1 Controls Drive
Shelton, Connecticut 06484
(Address of principal executive offices and zip code)
(203) 937-6137
( Company’s telephone number, including area code)
secfilings.nasdaq.com/filingFrameset.asp?FilingID=13229193&RcvdDate=2/14/2019&CoName=NANOVIRICIDES%2C%20INC.&FormType=10-Q&View=html
|
